Amarantus BioScience Holdings, Inc. is a development-stage, publicly-traded biotechnology company discovering & developing first-in-class treatments for diseases associated with the dysfunction of a wide range of biological pathways, including protein misfolding, cell cycle dysregulation, neurodegeneration and apoptosis (Programmed Cell Death).
Degenerative disorders such as Parkinson’s, Alzheimer’s, Retinitis Pigmentosa, Diabetes and ALS as well as Cardiovascular Disease such as Myocardial Infarction, Angina, Coronary Artery Disease and Heart Failure are in need of treatments that address the region specific apoptosis associated with each disorder. The Company has a focus on developing certain small molecules, biologics, and biomarkers surrounding the intellectual property and proprietary technologies it owns and to which it has licenses to treat and/or diagnose Parkinson’s disease, Alzheimer’s disease, Retinitis Pigmentosa and other human diseases.
Amarantus has a license to Eltoprazine, owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and has a license to the LymPro Test®.
Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments and diagnostics in development for concussions and TBI. The Company believes that TBI-induced neurodegeneration represents a new frontier of clinical research which may ultimately allow for commonalities between chronic degenerative disorders.
Amarantus BioScience Holdings, Inc. intends to advance its therapies and diagnostics to provide patients with safe and effective treatment options in the care of their illnesses.
Eltoprazine is a 5HT1a/1b partial agonist small molecule drug candidate originally developed by Solvay, S.A. (now Abbvie) with positive human clinical data produced in a Phase 2a trial for the treatment of LID associated with PD, Attention Deficit Hyperactivity Disorder and Cognition . Eltoprazine has been evaluated in a number of neurology-focused indications and has a well-established safety profile, having been administered to over 700 patients to date.
MANF is a highly potent, neurotrophic factor currently in pre-clinical development for the treatment of several apoptosis-related disorders. Coming after other selective neurotrophic factors such as GDNF, Neurturin, NGF, and others, MANF’s discovery protocols, utilizing our proprietary PhenoGuard Protein Discovery Engine were designed to identify a molecule that would be highly selective for dopamine producing neurons of the Substantia Nigra. MANF represents a new family of neurotrophic factors with mechanisms of action fundamentally differentiated from its predecessors.
MANF is an endogenous, highly-conserved, ubiquitously expressed and highly potent secreted human growth factor up-regulated in the adaptive pathway of the Unfolded Protein Response resulting in the prevention of apoptosis. This cell death is associated with several devastating human diseases and injury related disorders. By mediating this critical biological process, MANF is indicated for the treatment of several poorly served medical conditions, including Retinitis Pigmentosa, Parkinson’s disease, Wolfram’s Syndrome, Diabetes, Ischemic Heart Disease and Traumatic Brain Injury.
The Lymphocyte Proliferation Test (LymPro Test ®) is a diagnostic blood test that measures the ability of peripheral blood lymphocytes to withstand an external stimulation inducing them to enter the cell cycle. It is hypothesized that certain diseases are the result of a compromised cellular machinery that leads to abhorrent cell cycle re-entry by neurons.
The inventive step for LymPro that makes a unique asset involves using peripheral blood lymphocytes (PBLs) as a surrogate for neuronal cell function, suggesting a common immune-based relationship between PBLs and neurons in the brain.
LymPro Test ® is currently being developed as a diagnostic blood test for Alzheimer’s disease and is being evaluated as a diagnostic blood test for Traumatic Brain injury and Chronic Traumatic Encephalopathy.
Current Status: The Parkinson’s disease application of the NuroPro® Blood Test has completed proof-of-concept and Phase 1 clinical validation studies. Amarantus is preparing the Phase 2 validation study required to gain Clinical Laboratory Improvement Amendments (CLIA) certification. Upon CLIA certification, the Company intends to begin the commercial sale of the NuroPro Parkinson’s Disease Blood Test.
The NuroPro Blood Test is Amarantus’ diagnostic platform for the early detection of neurodegenerative diseases. It is being developed as a tool to assist physicians to more accurately diagnose disease and monitor progression. The platform involves monitoring the concentration of 57 protein markers in blood serum identified to be linked to neurodegeneration in order to accurately detect and distinguish between Alzheimer’s disease, ALS (Lou Gehrig’s disease), and Parkinson’s disease. Amarantus’ license is focused on the further development of a subset of 21 of these protein markers specifically targeting early diagnosis and ongoing monitoring of Parkinson’s disease. Given the length of time it takes to accurately diagnose Parkinson’s disease and the relatively high early misdiagnosis rates, the development of a blood-based biomarker test is likely to generate significant interest among neurologists and primary care physicians as it will allow them to intervene at an earlier stage in disease progression.
Amarantus Therapeutics has developed a robust discovery platform PhenoGuard Protein Discovery Engine that allows Amarantus scientists to rapidly discover novel secreted human proteins with biological activity for specific indications. Our Platform consists of our PhenoGuard Cell Line Library and highly sensitive Target Validation cell culture systems that provide accurate results and allow our scientists to make better go/no-go decisions. The first application of our Protein Discovery Engine was in the discovery of MANF from astrocytes.
c/o Janssen Labs @ QB3
953 Indiana Street
San Francisco, CA 94107
Phone: (408) 737-2734
Fax: (408) 852-4427
Aimee Boutcher, Director of Investor Relations
Phone: (408) 737-2734 x 101
Forward Looking Statements
Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements." These forward-looking statements generally are identified by the words believes," project," expects," anticipates," estimates," intends," strategy," plan," may," will," would," will be," will continue," will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.